A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration
Status:
Withdrawn
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
From 3 large patient databases, patients diagnosed with AMD who have never taken
levodopa(L-DOPA) containing medications have a mean age of diagnosis at 71 years. Patients
who have been treated with L-DOPA containing medications have a mean age of diagnosis of AMD
at 79 years.
L-DOPA binds to GPR143 in the retinal pigment epithelium, and releases PEDF, which protects
the retina and downregulates VEGF, which is the cause of neovascularization.
The Investigators will evaluate the safety and tolerability of carbidopa-levodopa in patients
with AMD, and measure the effects on surrogate functional biomarkers of AMD.
Phase:
Phase 2
Details
Lead Sponsor:
Snyder, Robert W., M.D., Ph.D., P.C.
Treatments:
Carbidopa Carbidopa, levodopa drug combination Levodopa